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Abstract: Hürthle cell carcinoma (HCC) can present either as a minimally invasive or as a 
widely invasive tumor. HCC generally has a more aggressive clinical behavior compared with 
the other differentiated thyroid cancers, and it is associated with a higher rate of distant metas-
tases. Minimally invasive HCC demonstrates much less aggressive behavior; lesions ,4 cm can 
be treated with thyroid lobectomy alone, and without radioactive iodine (RAI). HCC has been 
observed to be less iodine-avid compared with other differentiated thyroid cancers; however, 
recent data have demonstrated improved survival with RAI use in patients with HCC .2 cm 
and those with nodal and distant metastases. Patients with localized iodine-resistant disease 
who are not candidates for a wait-and-watch approach can be treated with localized therapies. 
Systemic therapy is reserved for patients with progressive, widely metastatic HCC.
Keywords: thyroid cancer, thyroid nodule, follicular cell carcinoma, Hurthle cell lesion, 
minimally invasive HCC
Hürthle cell cytology, genotype, and clinical 
behavior
The oncocytic follicular cells of the thyroid continue to carry the name “Hürthle cells”, 
even though the cells that Karl Hürthle initially identified in 1894 ultimately proved 
to be the parafollicular C cells (Hürthle 1894).1 They are large, polygonal cells with 
marked eosinophilic, granular cytoplasm reflective of overly abundant mitochondria 
(Figure 1). Hürthle cells can be observed in both benign and malignant conditions of 
the thyroid gland. The mechanism behind mitochondrial abundance in these conditions 
is not completely understood; however, it is likely a reflection of excessive mitochon-
drial proliferation and/or decreased mitochondrial degradation (mitophagy). Oncocytic 
metaplasia occurs in many organs of the body secondary to various cellular stress 
responses. In the thyroid, oncocytic changes are associated with such benign condi-
tions as cell-mediated autoimmune thyroiditis (Figure 2), humoral-mediated hyper-
thyroidism (Graves disease), and hyperplastic nodules seen in multinodular goiters.2 
Focal oncocytic trans-differentiation results in neoplasia consisting predominantly of 
Hürthle cells that can represent benign Hürthle cell adenomas or malignant Hürthle cell 
carcinomas (HCCs). The histologic distinction between adenoma and carcinoma can 
generally only be definitively made on histologic examination of a resection specimen; 
like other follicular lesions, it is determined by the presence or absence of capsular 
and/or vascular invasion, which are the hallmarks of HCC (Figure 3). Oncocytic 
follicular cells are also seen in the oncocytic variant of papillary thyroid carcinoma, 
which is a rare subtype of papillary thyroid carcinoma. Variable biological behaviors 
have been reported for the oncocytic variant of papillary thyroid carcinoma, which is 
histologically defined by the presence of oncocytes (at least 75% of the entire tumor) 
seen along with the classic nuclear features of papillary thyroid carcinoma.2–5
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HCC was first described by Ewing in 1928; it represents 
only 3% of all thyroid cancers6 and is currently classified 
as a variant of follicular carcinoma according to the World 
Health Organization (WHO).7 However, recent data have 
called into question whether HCC is indeed a variant of 
follicular carcinoma or a distinct entity with a different 
mutational profile, unique pathologic signature, and clinical 
behavior. A recent study of 27 Hürthle cell tumor samples 
(8 Hürthle cell adenomas, 9 minimally invasive HCCs, and 
10 widely invasive HCCs) used mass spectrometry-based 
genotyping to interrogate hot spot point mutations in the 
most common thyroid oncogenes, and real-time polymerase 
chain reaction was used to assess for common oncogenic 
fusions.8 Transcriptomes for widely invasive HCC were 
compared with follicular carcinoma expression array profiles 
obtained from the Gene Expression Omnibus. The authors 
reported only 11% RAS mutations and no Pax8-PPARγ rear-
rangements in HCC tumor samples; in contrast, follicular 
carcinomas had a 45% RAS mutation rate and rearrangements 
of Pax8-PPARγ in 25%–60% of cases. This study also showed 
that the chromosomal copy number profiles of HCCs were 
distinct from follicular carcinomas, as large regions of gain 
on chromosomes 5, 7, 12, and 17 are observed in HCC, but 
they are not seen in follicular carcinoma.
HCC is subdivided based on histology into either mini-
mally invasive or widely invasive subgroups. Minimally 
invasive carcinomas are fully encapsulated tumors with 
microscopically identifiable foci of capsular or vascular 
invasion (,4 foci), in contradistinction to widely invasive 
tumors, which have extensive vascular invasion (.4 foci) 
and extrathyroidal invasion. However, there is a lack of 
consensus in the literature, as some centers consider encap-
sulated tumors with only microscopic capsular invasion to 
be minimally invasive HCCs, whereas encapsulated tumors 
with minimal vascular invasion (,4 foci) are classified sepa-
rately. Patients with a minimally invasive encapsulated HCC 
(microscopic capsular invasion with no vascular invasion) 
often experience a good prognosis.9
Studies have reported that HCC with focal vascular 
invasion (,4 foci) can also be associated with less aggres-
sive behavior similar to that of HCCs with minimal cap-
sular invasion and no vascular invasion. In a retrospective 
single-institutional study by Xu et al, the experience of 
276 patients with encapsulated differentiated thyroid cancers 
(224 encapsulated papillary thyroid cancers, 34 encapsulated 
follicular carcinomas, and 16 encapsulated HCCs) showed 
that extensive vascular invasion ($4 foci of vascular inva-
sion) is an independent predictor of recurrence in patients 
with encapsulated differentiated thyroid cancers; indeed, the 
risk of recurrence was 42% in patients with extensive vascular 
invasion compared to 1% in patients with no vascular inva-
sion or focal vascular invasion (,4 sites).10 In a retrospec-
tive, single-institution study of 50 patients with encapsulated 
Figure 1 Oncocytes (Hürthle cells) showing characteristic abundant, granular 
eosinophilic cytoplasm and prominent nucleoli (hematoxylin and eosin, ×40).
Figure 2 Prominent oncocytic change in chronic lymphocytic thyroiditis. Abundant 
lymphocytes with germinal center formation are present (hematoxylin and eosin, ×10).
Figure 3 vascular invasion in a Hürthle cell carcinoma (hematoxylin and eosin, ×2).
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HCC, Ghossein et al also reported that the pathologic finding 
of .4 foci of vascular invasion is the most powerful predic-
tor of recurrence and compromised recurrence-free survival 
(P,0.001) among patients with encapsulated HCC. In this 
study, patients with no vascular invasion or ,4 foci of vas-
cular invasion had 100% recurrence-free survival at 5 years 
compared to 20% recurrence-free survival among patients 
with .4 foci of vascular invasion.11
Factors other than vascular invasion have been reported 
to be associated with overall survival in patients with HCC. 
Goffredo et al identified 3,311 patients .18 years of age with 
a diagnosis of HCC and 59,585 patients with papillary and 
follicular thyroid cancers from the Surveillance, Epidemiol-
ogy and End Result (SEER) database from 1988 to 2009 and 
determined that older age, larger tumor size, extrathyroidal 
tumor extension, and not undergoing surgery were inde-
pendently associated with reduced overall survival among 
patients with HCC. HCC was more common in older men, 
and it appeared to be more aggressive compared to other dif-
ferentiated thyroid cancers.12 In another study, Chindris et al 
identified 173 patients with HCC between 2001 and 2012; 
male gender and American Joint Committee on Cancer TNM 
(AJCC-TNM) Stages III–IV were independent risk factors 
for recurrence or death among patients with widely invasive 
HCC. The cumulative risk of recurrence or death within 
5 years of diagnosis was 91% in men with Stages III–IV 
disease compared to 74% in women with the same stages 
of disease; the 5-year cumulative probability of recurrence 
or death in patients with AJCC-TNM Stages I–II was 0% 
among women compared to 17% among men.13
Diagnosis
One of the fundamental obstacles to expedited treatment 
is our inability to establish the diagnosis of HCC preop-
eratively, either radiologically or with cytology based on 
fine needle aspiration (FNA). In the absence of identifiable 
invasive or metastatic disease on imaging studies, it is usu-
ally impossible to distinguish between a benign Hürthle cell 
process or neoplasm and HCC; for this reason, histologic 
evaluation based on a surgical specimen is generally neces-
sary. Ultrasound alone is unable to distinguish HCC from 
other histologic variants, as it can clinically demonstrate a 
spectrum of sonographic findings from hypoechogenicity to 
hyperechogenicity14 (Figure 4).
FNA diagnosis of a Hürthle cell neoplasm (HCN) can 
typically be classified as a follicular lesion (FLUS) or atypia 
of undetermined significance (AUS) with Hürthle cell 
features (AUS/FLUS/Hürthle cell lesion of undetermined 
significance [HLUS], Bethesda III). Both benign and malig-
nant oncocytic lesions can demonstrate marked cytologic 
atypia, complicating the process of diagnosis on biopsy alone 
(Figure 5). Overall, the projected risk of malignancy for 
this diagnostic category is 5%–15%. A cytologic diagnosis 
of suspicious for HCN (Bethesda IV) carries a projected 
15%–30% risk of malignancy.15 However, the true risk of 
malignancy for each Bethesda diagnostic cytologic category 
varies by institution, and such institutional data should be 
examined regularly and made available to clinicians.16,17 
In patients with a cytologic finding of a HLUS, possible 
management strategies include repeat ultrasound-guided 
FNA (potentially paired with molecular testing) and close 
surveillance if the molecular testing is reassuring, or surgical 
excision for the purpose of definitive diagnosis. In patients 
with FNA cytology demonstrating a HCN, diagnostic surgi-
cal excision should be performed if molecular testing is not 
done or if it is inconclusive.9
Several studies have examined clinical variables that 
may be more indicative of malignancy in patients with FNA 
results that are suspicious for a HCN (Bethesda IV). In a 2010 
retrospective single-institution study, Kim et al reviewed 
RIGHT SAG
LS7 LS7
2
3
2
3
L  3.28 cm1 1 L  1.88 cm
LEFT SAG MIDA B
Figure 4 (A) Hürthle cell carcinoma. (B) Hürthle cell adenoma. Both nodules have similar ultrasound characteristics.
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clinical features, preoperative imaging, and pathology reports 
of 57 patients with an FNA cytology consistent with HCN 
who underwent thyroidectomy. This study reported that on 
multi-logistic regression, patients with nodules .1.5 cm 
have a higher risk of being associated with a thyroid malig-
nancy compared to those with nodules ,1.5 cm (odds ratio 
8.00; 95% confidence interval [CI] 1.92–33.37). This is 
even more pronounced in older patients, as the predicted 
probability of malignancy in patients .45 years of age with 
a tumor .1.5 cm reached 65% in this study.18 It should 
be noted that this study examined the risk of any thyroid 
malignancy and included 9 papillary carcinomas and 
7 follicular carcinomas in addition to 10 HCCs. A similar 
retrospective single-institution study by Giorgadze et al 
reviewed 169 FNAs that were associated with a cytologic 
diagnosis of a HCN and reported that the overall risk of 
thyroid malignancy was 55% for nodules $2 cm compared 
to 45% for nodules ,2 cm (P,0.0001). Malignancy risk 
was also higher in older patients, as 82% of nodules among 
patients .40 years of age represented a thyroid cancer vs 
18% in those ,40 years of age (P,0.0001).19 Again, the 
specificity of these findings for HCC is limited, as this study 
included 53 cases of HCC, 19 cases of papillary carcinoma, 
3 follicular carcinomas, and 1 medullary carcinoma.
Examination of factors related specifically to the likeli-
hood of HCC is limited, as many of the studies examining 
this question have been small, single-institution, retrospective 
reviews. A 1998 study by Chen et al found that nodule size is 
the most significant predictor of malignancy. Of 57 patients 
examined, 20 had HCC, and their tumors were significantly 
larger (4.0±0.4 cm) than those with Hürthle cell adenomas 
(2.4±0.2 cm).20 A summary of similar studies is presented 
in Table 1. Tumor size consistently has been shown to be 
associated with the increased probability that an HCN on 
FNA will prove to be a HCC. It should be noted that most 
of these studies were done prior to formalization of FNA 
cytology criteria according to the Bethesda schema, and it 
is unclear as to how these findings would translate into the 
current Bethesda lexicon. More robust data are needed before 
clear criteria can be defined for establishing the likelihood 
of HCC in the preoperative setting.
Table 1 Clinical studies examining factors associated with HCC
References Year N Significant variables
20 1998 55 (20 HCCs) Size 4.0±0.4 cm HCC vs 2.4±0.2 cm benign; P,0.005
Malignancy rate for .4 cm: 65%
32 2002 56 HCCs (23 Mi, 33 wi) 22% of Mi HCC tumors .4 cm vs 75% of wi HCC tumors .4 cm
19 2004 169 (53 HCCs, 19 PTCs, 
3 FCCs, 1 medullary)
Size: 55% cancer for HCN $2 cm vs 45% for HCN ,2 cm, P,0.0001
Age: 82% cancer for HCN $40 years vs 18% for HCN ,40 years, P,0.0001
Risk of HCC not specifically analyzed
67 2008 55 (9 HCCs) Age: 66±6 years HCC vs 53±2 years benign, P=0.001
Size: 4.5±0.7 cm HCC vs 2.5±0.2 cm benign, P,0.001
Malignancy rate for .4 cm: 44%
68 2008 57 (12 HCCs) Size: mean 5.1 cm HCC vs 2.7 cm benign, P,0.001
Malignancy rate for .4 cm: 55%
Malignancy rate for .6 cm: 100%
69 2010 57 (28 HCCs) Size: mean 3 cm HCC vs 1.8 cm benign, P=0.003
Malignancy rate for .3 cm: 83%
18 2010 57 (10 HCCs, 9 PTCs, 
7 FCCs)
Size: OR 8.0 (95% Ci 1.92–33.37) for any thyroid cancer in HCN nodules .1.5 cm
Risk of HCC not specifically analyzed
13 2015 173 HCCs (44 Mi,  
126 wi, 3 PD)
Size: mean 4.0 cm wi HCC vs 2.7 cm Mi HCC
44.9% of wi HCC tumors were .4 cm vs 7% of Mi HCC tumors
Abbreviations: HCC, Hürthle cell carcinoma; wi, widely invasive; Mi, minimally invasive; PTC, papillary thyroid carcinoma; FCC, follicular cell carcinoma; HCN, Hürthle 
cell neoplasm; OR, odds ratio; CI, confidence interval; PD, poorly differentiated.
Figure 5 Oncocytic change in lymphocytic thyroiditis on fine-needle aspiration 
cytologic smear showing marked cytologic atypia, with abundant nuclear contour 
irregularities and grooves (arrow) (Papaniolau stain, ×40).
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Molecular marker analysis in thyroid cytology has been 
studied predominantly in thyroid nodules with indeterminate 
cytology. The 3 commercial tests for which the most data are 
available in validation trials are the Afirma Gene Expression 
Classifier (GEC, mRNA expression of 167 genes),21 a 7-gene 
panel of genetic mutation and rearrangement testing,22 and a 
newer multiplexed next-generation sequencing (NGS) panel 
examining .400 known drivers of oncogenesis in thyroid 
cancer (ThyroSeq).9
Alexander et al employed the GEC to evaluate 265 
nodules with Bethesda III, IV, and V cytology results over 
19 months in a prospective, multicenter blinded study. 
All thyroid nodules were $1 cm, and all study subjects 
had corresponding histological specimens along with fine 
needle biopsies. The negative predictive value (NPV) and 
positive predictive value (PPV) of the GEC were 95% and 
38%, respectively, for aspirates classified as AUS or FLUS 
(Bethesda III), and 94% and 37% for aspirates classified 
as follicular neoplasm/HCN or suspicious for follicular 
neoplasm (Bethesda IV). However, of the 21 patients with 
Hürthle cell adenomas in this study, 17 (81%) were classi-
fied as “suspicious” on the GEC. In this setting, use of the 
GEC in Hürthle cell lesions may well be associated with 
a relatively high false-positive result rate.21 McIver et al 
employed the GEC to evaluate 60 nodules that were reported 
to be either suspicious for follicular neoplasm/HCN or AUS/
FLUS in patients who were not at high risk for malignancy 
(no history of head and neck irradiation, no family history 
of thyroid cancer, no prior history of thyroid cancer, and no 
worrisome imaging characteristics). There were 31 patients 
with cytologies suspicious for follicular neoplasm/HCN who 
underwent surgery; 27 of these patients had suspicious GEC 
results, and 4 were found to be malignant. PPV and NPV 
of the GEC were 15% and 75%, respectively, for aspirates 
classified as suspicious for follicular neoplasm/Hürthle call 
neoplasm.23 In another study, Brauner et al studied 72 patients 
with cytologies suspicious for HCN or AUS/FLUS with a 
predominance of Hürthle cells who underwent GEC test-
ing between 2010 and 2014. Forty-five (63%) GEC results 
were classified as suspicious for malignancy; 43 (96%) 
of these patients underwent surgery, and 6 (14%) were 
found to be malignant.24 Similarly, Lastra et al found that 
only 15% (2 of 13) of patients with a cytology suspicious 
for HCN and suspicious GEC harbored a malignancy.25 
Wu et al also found an increased rate of “suspicious” 
GEC results in nodules with Hürthle cell predominance 
(77.4% vs 50.5% for nodules without Hürthle cell predomi-
nance, P,0.01), but there was no difference in the rate of 
malignancy (25.8% vs 25.3%).26 Together, these data raise 
concern that there is an increased rate of suspicious GEC 
results in Hürthle cell lesions despite there being a relatively 
low risk of malignancy on surgical histology.
Nikiforov et al studied a panel of common thyroid 
cancer mutations, including BRAFV600E, NRAS, HRAS, and 
KRAS, as well as RET/PTC and Pax8/PPARγ rearrange-
ments, in 1,056 consecutive thyroid FNA samples with 
Bethesda III, IV, and V cytology results and reported a PPV 
of 87%–95%. The NPV of the same mutational panel was 
86% for Bethesda IV cytology and 94% for Bethesda III 
cytology.22 However, there were only 11 follicular carcino-
mas in the study cohort, and the published results did not 
specify whether any of these were oncocytic in nature and 
consistent with a HCC. Mutations were detected in only 5 of 
11 follicular carcinoma samples (4 RAS and 1 Pax8-PPARγ), 
yielding a sensitivity of 45% for this histology subgroup. As 
RAS mutations are less common (and Pax8-PPARγ muta-
tions nonexistent) in HCC compared to follicular carcinoma,8 
it would follow that this limited mutation panel testing is less 
reliable in detecting HCC.
More recently, Nikiforov et al applied NGS technol-
ogy to greatly expand the simultaneous testing of thyroid 
cancer-related genetic markers (ThyroSeq V2) in thyroid 
FNA samples. In a series of 143 nodules (39 malignant) with 
the cytologic diagnosis of follicular neoplasm/suspicious 
for follicular neoplasm, the test performance yielded a 90% 
sensitivity, 93% specificity, 96% NPV, and 83% PPV27 for 
detection of any thyroid malignancy based on final surgical 
pathology. The study included only 3 HCC cases, of which 2 
had a mutation detected, and the lesion with a false-negative 
result was reported as a minimally invasive HCC. Therefore, 
use of molecular testing in the evaluation of thyroid nodules 
with Hürthle cell cytologic features should be understood 
to have limitations, as HCC has had a limited representa-
tion in most clinical studies. Molecular testing should not 
replace clinical judgment and consideration should be given 
to the pretest probability of malignancy based on clinical 
risk factors, ultrasound imaging, and cytologic findings in 
interpreting the results of any molecular marker testing of 
FNA specimens.
Stratification of risk
HCC is currently designated by the WHO as a histopatho-
logic variant of follicular carcinoma, and this is echoed in the 
American Thyroid Association (ATA) and National Com-
prehensive Cancer Network (NCCN) treatment guidelines, 
with HCC following the same risk stratification as that of 
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follicular carcinoma. For the ATA, intrathyroidal encapsulated 
tumors with minor capsular or vascular invasion (,4 foci) 
or #5 metastatic lymph nodes where the foci of metastases 
are ,0.2 cm are considered to be low risk. Intermediate 
risk of recurrence is defined by vascular invasion, minimal 
extrathyroidal extension, or .5 metastatic lymph nodes 
(0.2–3 cm). High-risk patients include those with macroscopic 
extrathyroidal extension, incomplete tumor resection, distant 
metastases, or metastatic lymph nodes .3 cm.9 The NCCN 
guidelines for HCC (Version 1.2016) describe minimal vas-
cular invasion as a few microscopic foci (#4) of invasion in 
an intrathyroidal HCC. The NCCN guidelines assign these 
patients to a low-risk group.28
Surgical management of HCC
The mainstay of treatment for all differentiated thyroid can-
cers is surgical resection, and HCC is no exception. Indeed, 
due to the relatively reduced avidity of HCC for radioactive 
iodine (RAI) and the resultant compromised efficacy of treat-
ment, the completeness of surgical resection is of paramount 
importance. Since it is impossible to make the cytologic 
diagnosis of HCC preoperatively, the 2 key decision points 
in surgical management are that of planning the initial extent 
of surgery and whether further surgical resection (completion 
thyroidectomy) is warranted once the diagnosis of HCC is 
histologically confirmed.
In general, thyroid surgery is approached with preference 
for diagnostic thyroid lobectomy unless clinical features 
prompt considering removal of the entire thyroid gland at 
the primary surgery. A personal history of craniocervical 
radiation does not increase the risk of HCC; however, it is 
an independent risk factor for developing papillary thyroid 
cancer, and significant exposure (particularly in childhood 
or adolescence) warrants upfront total thyroidectomy.9 Other 
clinical considerations that would prompt initial total thyroi-
dectomy include presence of dominant contralateral nodules 
or preexisting diminished hormone production necessitating 
thyroxine replacement.9
As previously discussed, the predominant clinical feature 
associated with an increased risk of HCC in those patients 
with indeterminate Hürthle cell findings on FNA is the size 
of the nodule (Table 1). A nodule $4 cm is associated with 
an increased risk of HCC, and the ATA guidelines accord-
ingly prescribe upfront total thyroidectomy.
A thorough history and physical examination are critical 
in the initial evaluation of patients with the potential diag-
nosis of HCC, since dysphagia, dyspnea, and voice change 
as well as the physical examination finding of a palpable 
hard, immobile mass are concerning for an invasive pro-
cess. Preoperatively, these patients need laryngoscopy to 
evaluate vocal cord function and the integrity of the recurrent 
laryngeal nerves. Cross-sectional imaging such as computed 
tomography (CT) and magnetic resonance imaging (MRI) 
is essential in patients with a suspicion for locally advanced 
disease, including concern for invasion of the aerodigestive 
tract and/or major vessels of the neck, as it can visualize 
deeper anatomic compartments not readily imaged by ultra-
sound. In the past, clinicians were advised against CT per-
formed with intravenous contrast, as the iodine load was felt 
to delay treatment with RAI; however, more recent studies 
have clarified adequate clearance of this iodine, with return 
of urinary iodine levels to baseline within 1 month for most 
patients with normal renal function.29
HCC is classified as a variant of follicular carcinoma; 
as a result, many believe that it spreads hematogenously, 
with rare lymph node metastasis as is the case for follicular 
carcinoma.30 However, several studies have documented 
lymph node metastasis in 5.3%–13% of HCC cases.12,13,31,32 
Therefore, the finding of a HCN should prompt thorough 
ultrasound evaluation of all compartments of the neck prior 
to surgery. In a study of 39 cases of HCC, 3 (8%) were found 
to have lymph node metastasis at presentation (1 ipsilateral 
central compartment, 2 ipsilateral central and lateral neck 
compartments) and warranted neck dissections.31 All 3 cases 
of node-positive disease were associated with a primary 
tumor .5 cm in size. Another study examining 173 HCCs 
treated from 2001 to 2012 found a 9.2% incidence of node-
positive disease; all cases were associated with a widely inva-
sive or poorly differentiated phenotype.13 Seven of 173 cases 
(4.0%) were limited to the central compartment, while 9 
(5.2%) involved the lateral compartments. The largest study 
to date examined 3,311 cases of HCC, with documentation of 
node-positive disease in 5.3%.12 Implications of this study are 
limited, since only 73.9% of patients had any lymph nodes 
pathologically examined.
Once an HCC is histologically confirmed following diag-
nostic thyroid lobectomy, consideration should be given to 
performing a completion thyroidectomy. Minimally invasive 
HCC is considered to be at a low risk of recurrence by both 
the ATA and NCCN guidelines, and is very often treated 
with lobectomy alone. In one of the large clinical studies 
examining outcome for minimally invasive HCC, all 39 cases 
(100%) were found to be without evidence of recurrence 
or disease-specific mortality, with a median follow-up of 
69.8 months.13 However, most patients were indeed treated 
with either total thyroidectomy or lobectomy followed by 
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completion thyroidectomy. Of 23 patients with minimally 
invasive HCC treated over 60 years, none experienced a 
recurrence or succumbed to their disease.32 The majority 
(88%) of patients with minimally invasive HCC were man-
aged conservatively with thyroid lobectomy alone.
Thyroid cancers ,1 cm usually do not prompt aggressive 
surgical treatment or completion thyroidectomy. However, 
it is important to note that not all sub-centimeter thyroid 
cancers have the same excellent prognosis. Hürthle cell 
histology is reported to be an independent risk factor for 
reduced survival even among tumors that are ,1 cm. Study-
ing 564 cases of follicular carcinomas (N=371) and HCCs 
(N=193) ,1 cm compared to 22,174 cases of papillary 
thyroid microcarcinomas from the SEER database between 
1988 and 2009, Kuo et al reported that follicular and Hürthle 
cell histologies remain independent risk factors for reduced 
10-year disease-specific survival even after adjustment for 
patient age, type of surgery, RAI treatment, extrathyroidal 
extension, and nodal and distant metastases (hazard ratio 5.3, 
95% CI 2.78–10.10).33
In cases of widely invasive HCC, the risk of recurrence 
is 73%, and therefore, they should be placed in the ATA 
intermediate- or high-risk categories, prompting adjuvant 
treatment with RAI.32 For these patients, completion thyroi-
dectomy is mandated.
Adjuvant treatment
Thyroxine suppression
Differentiated thyroid cancer cells express the thyroid-
stimulating hormone (TSH) receptor and respond to TSH 
by promoting cell division and tumor growth. Employing 
supra-physiological doses of levothyroxine can suppress TSH 
levels, potentially decreasing the risk of recurrence.9 The goal 
for the degree of TSH suppression following surgery is deter-
mined by the patient’s overall risk of recurrence, incorporat-
ing the patient’s response to therapy as well as any comorbid 
conditions that could be associated with an increased risk of 
complications with prolonged TSH suppression. Completely 
resected minimally invasive HCC is categorized by both the 
ATA and NCCN as being at low risk of recurrence, and it 
does not require TSH-suppressive therapy; serum TSH may 
be kept within the low-normal reference range (0.5–2 mU/L). 
In patients with structurally incomplete response to therapy, 
serum TSH should be kept at ,0.1 mU/L indefinitely, unless 
there is a contraindication. In patients with an incomplete bio-
chemical response to therapy and those with high-risk HCC 
and an excellent or indeterminate response to therapy, TSH 
should be maintained at between 0.1 and 0.5 mU/L, taking 
into account thyroglobulin levels, trends in those levels over 
time, and the risks of TSH suppression.9
Radioiodine
Overall, treatment with RAI is not routinely recommended 
in patients at a low risk of recurrence; it should be reserved 
for patients at an intermediate or high risk of recurrence. 
Examining the utility of RAI in minimally invasive follicular 
carcinoma and HCC, Goffredo et al identified 617 minimally 
invasive follicular carcinomas in the National Cancer Data 
Base (NCDB); 333 had only capsular invasion, and 284 had 
minor vascular invasion with or without focal capsular inva-
sion. They found that 75% of the minimally invasive follicu-
lar carcinoma group with only capsular invasion underwent 
total thyroidectomy, and 52.6% received RAI; in comparison, 
72.9% of the minimally invasive follicular carcinoma group 
with only vascular invasion underwent total thyroidectomy, 
and 62.1% received RAI. These findings demonstrate that 
US health care providers have been managing minimally 
invasive follicular carcinoma more aggressively than sug-
gested by guidelines, which could be due to the absence 
of consensus across pathologists, experts, and guidelines 
regarding criteria for the diagnosis of minimally invasive 
follicular carcinoma.34
There is controversy with regard to RAI avidity of HCC 
and the effect of RAI treatment on survival of patients with 
HCC. Most studies that have evaluated the efficacy of RAI 
for HCC are small, retrospective, single-institutional series, 
likely due to the rarity of HCC.
In an old study, Lopez-Penabad et al reviewed 127 patients 
with HCN (89 patients with HCC and 38 patients with Hürthle 
cell adenoma) who were treated from 1944 to 1955 and 
reported 38% RAI avidity in patients with HCC. This study 
showed that RAI therapy is associated with survival benefit 
in patients with HCC when it is used primarily for ablation 
rather than when residual disease is believed to be present.35 
In a retrospective single-institution study, Besic et al reviewed 
16 patients with HCC and distant metastases; all these 
patients underwent thyroid hormone withdrawal. Scanning 
demonstrated uptake (range 0.1%–12%) in 11 of 16 patients 
(69%).36 In another study, Besic et al evaluated 30 HCC 
patients with distant metastases and reported RAI uptake in 
metastases in 16 of 30 patients (53%), with uptake of $0.5% 
in 9 of 30 patients (30%).37 At a nationwide level, Jillard 
et al identified 1,909 patients with HCC who underwent 
total thyroidectomy in the NCDB between 1998 and 2006. 
Patients were included if they had AJCC-TNM pT1 tumors 
with N1or M1 disease, and pT2–4 tumors with any N or M 
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disease status. This study showed an association between 
use of adjuvant RAI and improved survival among patients 
with HCC. Five- and 10-year survival for patients with 
tumors measuring 2–4 cm who received RAI were improved 
compared with those who did not receive RAI (97.8% and 
87.8% vs 94.1% and 71.9%, respectively; P,0.001). Five- 
and 10-year survival were also improved for patients with 
tumors .4 cm who received RAI compared to those who 
did not receive RAI (82.3% and 77.6% vs 62.3% and 56.9%, 
respectively; P,0.001). Therefore, the authors concluded that 
RAI is indicated in HCC patients who have tumors .2 cm 
and and/or nodal and distant metastases (Figure 6).38
Cervical radiation
External beam radiation therapy (EBRT) is another treatment 
option in patients with clinically evident gross extrathyroi-
dal extension that is incompletely resected. However, it is 
important to balance the potential benefit of radiation with 
potential complications, including dental decay, tracheal 
stenosis, esophageal stricture, osteonecrosis, fibrosis, and 
xerostomia.39 Intensity-modulated radiation therapy (IMRT) 
uses 3-dimensional (3D) CT to map the tumor and also 
computerizes dose calculations. It allows higher radiation 
doses to be delivered to the tumor and minimizes the dose 
received by surrounding tissues.40 In a study using the 
NCDB, 106,374 patients with differentiated thyroid cancer 
were evaluated; they included patients .18 years of age, 
without distant metastases, who underwent cervical radia-
tion therapy to assess the impact of IMRT vs 3D-conformal 
radiotherapy (3D-CT). Although not statistically significant, 
comparison of overall survival between patients undergoing 
IMRT vs 3D-CT demonstrated a hazard ratio of 0.67 (95% CI 
0.4–1.1; P=0.115) and trend toward improved overall sur-
vival with IMRT.41
The role of radiation as an adjuvant therapy in patients 
who have had complete resection of all locally invasive dis-
ease is controversial.42–46 In the absence of persistent gross 
residual disease, radiation is usually reserved for older patients 
(.50 years) with tumors that are more likely to be iodine-
refractory (including HCC) and who are at high risk of early 
cervical recurrence not amenable to surgical resection. Radia-
tion is seldom recommended as an adjuvant therapy in young 
patients, and especially those with iodine-avid tumors.
Directed therapy for distant metastasis
Targeted therapies in patients with advanced thyroid cancer 
are valuable tools to address malignant foci that arise in 
critical locations and that are at high risk of causing signifi-
cant morbidity or mortality secondary to tumor infiltration 
or compression of vital structures if they are not treated 
expeditiously.9 Such critical locations include the brain, 
spine, and bone (at risk of pathological fracture). Cervical and 
mediastinal disease places key airway structures (eg, trachea, 
larynx, major bronchi), as well as the digestive tract and great 
vessels, at risk. These lesions may require treatment prior to 
RAI therapy to prevent morbidity related to swelling that can 
occur in some of these metastatic foci. The choice of specific 
targeted therapy is dependent on tumor size and location, 
patient preference, and discussion between all members of the 
transdisciplinary disease management team. Frequently, this 
communication is best accomplished in a multidisciplinary 
tumor board setting.
The risk of bone metastases is likely increased in HCC 
patients. Bone metastases in patients with differentiated 
thyroid cancer including HCC are associated with significant 
morbidity, including pain and pathologic fracture.47 Surgery 
is the preferred treatment option for bone metastases that are 
associated with structural instability or that are in critical 
locations. A retrospective study of 109 patients with bone 
metastases from thyroid cancer (71% with follicular carci-
noma) reported that complete resection of bone metastases in 
young patients is associated with a significant improvement 
in survival.48 Radiotherapy plays an important role in treat-
ment of bone lesions, since it can be used in isolation or to 
complement surgery in cases of incomplete resection.9 In a 
retrospective study of 32 patients with metastatic HCC, Besic 
et al reported that the effect of EBRT on bone metastases 
lasted from 13 to 165 months (median, 93 months).37 Another 
treatment option is embolization of tumor vasculature; 
this can be used for pain control, and it can also be used in a 
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neoadjuvant fashion prior to surgical resection, as these bony 
metastases tend to be vascular and prone to intraoperative 
bleeding. Radiofrequency ablation has also been reported to 
reduce pain from thyroid cancer skeletal metastases.48–51
Localized therapies can also be effective treatment 
options for HCC that involves the respiratory tract and air-
ways. Options include bronchoscopy with laser therapy for 
intraluminal disease, endo-bronchial stenting to maintain 
patency of airways that are compressed or the subject of 
local invasion, surgical resection of the metastatic lesion, 
and focused EBRT.
Overall, brain metastases are uncommon; they are usually 
found in the setting of widespread metastatic disease and are 
associated with a very poor overall prognosis. High-dose 
glucocorticoids are usually recommended to decrease the 
surrounding edema once brain metastases are identified. 
Surgical resection is the preferred treatment option, unless 
the lesions are very small and/or mutifocal. Stereotactic 
radiation can be effective if ,3–5 small lesions are present, 
and whole-brain radiation is required when there are numer-
ous lesions.52–56
Systemic therapy
Some patients with widely metastatic HCC can survive for 
many years with only minimal disease progression, and they 
can remain relatively asymptomatic; thus, it is important to 
identify which patients will likely benefit from a wait-and-
watch approach vs systemic therapy. Factors related to the 
tumor, patient comorbidities, patients’ tolerance of treatment-
related morbidity and its impact on quality of life, and patient 
preference, all should be incorporated into these complex 
management decisions. It is unusual to initiate systemic 
therapy for lesions that are ,1 cm; however, not all metastatic 
lesions .1 cm require systemic therapy. Systemic therapy 
should be initiated sooner if metastatic lesions are in loca-
tions where continued growth would result in compromise of 
critical surrounding structures. Systemic therapy should be 
likely considered in the following cases: when patients have 
symptoms of weight loss, muscle wasting, or fatigue, or other 
constitutional symptoms attributable to their significant dis-
ease burden; when the rate of progression of structural disease 
is rapid enough that the disease is likely to cause morbidity; 
or when additional metastatic foci are identified.
Currently, sorafenib and lenvatinib are the only US Food 
and Drug Administration-approved multi-kinase inhibitors 
available for RAI-refractory differentiated thyroid cancer. 
Due to the relatively small number of such cases, there are 
no published studies examining outcomes of systemic therapy 
specifically for HCC. However, most published studies do 
report the response rate of HCC to treatment. A prospective 
randomized trial of lenvatinib vs placebo in the treatment 
of RAI-refractory thyroid cancer included 70 HCC cases 
(lenvatinib N=48, placebo N=22). Lenvatinib demonstrated 
a progression-free survival hazard ratio of 0.22 (95% CI 
0.10–0.51) in favor of treatment when compared to placebo.57 
The DECISION trial was a multicenter, randomized, double-
blind, placebo-controlled Phase III trial of sorafenib in 417 
RAI-refractory thyroid cancers; it included 74 HCC cases. 
The precise hazard ratio and CI for HCC were not published 
as part of the DECISION trial; however, sorafenib was 
reported to be associated with overall progression-free sur-
vival advantage among the subset of patients with HCC.58
Vandetanib has also been studied in a European Phase II 
trial in RAI-refractory differentiated thyroid cancer. Unfor-
tunately, the study included only 2 patients categorized as 
having follicular carcinoma with oncocytic features, and both 
were randomized to the placebo control group.59 A multi-
center, open-label, single-arm, Phase II study of axitinib in 
52 advanced thyroid cancers included 8 HCCs, of which 2 
demonstrated a partial response to treatment.60 There are cur-
rently several studies with active recruitment exploring the 
role of small-molecule inhibitors for iodine-refractory differ-
entiated thyroid cancer, including HCC. Based on Category 
2A evidence, the NCCN guidelines recommend that axi-
tinib, everolimus, pazopanib, and sunitinib be considered in 
patients with advanced HCC if clinical trials are not available 
or appropriate.61 In general, these small-molecule inhibitors 
can sometimes provide progression-free survival advantages 
with a side-effect profile that is tolerable in properly selected 
patients. However, they have not been shown to improve 
either disease-specific or overall survival, and specific drug 
activity in HCC is unlikely to be known due to the very small 
number of HCC cases included in most trials.
Prognosis and follow-up
HCC is associated with more aggressive clinical behavior 
compared to other differentiated thyroid cancers; for 
example, it is more often seen with a higher rate of distant 
metastases.12,33,35,62,63 In a retrospective study of 32 patients 
with metastatic HCC, Besic et al reported estimated 5- and 
10-year disease-specific survival rates of 81% and 60%, 
respectively.37
During initial follow-up of patients with HCC, serum 
thyroglobulin/thyroglobulin antibody (Tg/Tg Ab) levels on 
levothyroxine therapy should be measured every 6–12 months. 
In the ATA high-risk patients, more frequent measurements 
may be appropriate. Time intervals between serum Tg/Tg 
Ab measurement in the ATA low- to intermediate-risk HCC 
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patients can be lengthened to 12–24 months. The ATA high-
risk HCC patients and all patients with biochemically or 
structurally incomplete or indeterminate response to therapy 
should have Tg/Tg Ab levels measured every 6–12 months 
for several years.9
Cervical ultrasound to evaluate the thyroid bed, central, 
and lateral cervical nodal compartments should be performed 
every 6–12 months in patients with HCC initially following 
surgery, and then periodically depending on each patient’s 
risk of recurrence and unique response to therapy.9 RAI 
scanning has a high false-negative rate in patients with HCC 
due to the lack of iodine avidity in a majority of patients; 
therefore, it is not recommended as the principle imaging 
modality for surveillance.13 The ATA guidelines recom-
mend that fluorine-18-fluorodeoxyglucose positron emission 
tomography (FDG PET) be considered in patients with high-
risk differentiated thyroid cancers, and those cancers with 
elevated Tg levels and negative RAI scans. FDG PET may be 
considered as part of initial staging in patients with invasive 
HCC.9 Multiple studies have shown a high sensitivity of FDG 
PET for HCC. In a retrospective single-institution study of 
44 patients with HCC, Pryma et al reported a sensitivity of 
95.8% and specificity of 95% for FDG PET scans in patients 
with HCC.64 In a study of 12 patients with HCC, Lowe et al 
found that FDG PET had a sensitivity of 92%; they also 
noticed that half of the PET scans detected tumors not seen 
on conventional imaging, which resulted in a change in 
disease staging and management.65 In a retrospective study 
of 17 HCC patients, Plotkin et al reported a sensitivity of 
92%, specificity of 80%, PPV of 92%, and NPV of 80% for 
FDG PET/CT for identification of HCC.66
Cross-sectional imaging including CT and MRI of the 
neck and chest should be considered in the setting of bulky 
recurrent cervical disease, when potential aerodigestive tract 
invasion requires complete assessment, and in high-risk HCC 
patients with concern for lung metastases. Cross-sectional 
imaging of other organs including the brain, skeleton, and 
abdomen should be considered in high-risk HCC patients with 
elevated serum Tg and negative neck and chest imaging, and 
patients who have symptoms referable to those organs.9
Conclusion
There remains significant controversy with regard to optimal 
management of patients with HCC; it is more pronounced 
than the management of other forms of differentiated thyroid 
cancer, likely due to the relative rarity of the disease and scant 
high-quality evidence. Large multi-institutional studies are 
needed; until that time, utilization of national and nationwide 
data to assemble an adequate number of cases to inform valid 
conclusions will need to serve as a surrogate. Important 
questions that are outstanding include identification of the 
effect of minimal vascular invasion (1–4 foci) on the risk of 
recurrence and survival among patients with HCC, as well as 
measurement of the efficacy of adjuvant RAI in these patients. 
There also continues to be a need for consensus regarding the 
criteria needed to establish a diagnosis of minimally invasive 
HCC in order to avoid potential overtreatment.
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